IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.638
EU - Europa 830
AS - Asia 347
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 2.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.637
IE - Irlanda 413
SG - Singapore 186
CN - Cina 111
DE - Germania 111
UA - Ucraina 85
IT - Italia 60
CZ - Repubblica Ceca 42
SE - Svezia 37
FI - Finlandia 28
VN - Vietnam 19
TR - Turchia 15
BE - Belgio 13
GB - Regno Unito 13
IN - India 6
FR - Francia 5
RU - Federazione Russa 5
EU - Europa 3
JP - Giappone 3
PT - Portogallo 3
BG - Bulgaria 2
CH - Svizzera 2
ES - Italia 2
ID - Indonesia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
CA - Canada 1
CY - Cipro 1
IL - Israele 1
KR - Corea 1
LU - Lussemburgo 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
TJ - Tagikistan 1
Totale 2.821
Salva come PNG Salva come JPEG
Città #
Chandler 430
Dublin 413
Jacksonville 305
Singapore 157
Boardman 122
Ashburn 103
New York 65
Ann Arbor 61
Princeton 58
Lawrence 57
Brno 42
Wilmington 42
Munich 40
Beijing 38
Helsinki 26
Bremen 21
Dong Ket 18
Dearborn 17
Los Angeles 17
Brussels 13
L'aquila 13
Dallas 12
Izmir 10
Nanjing 10
Milan 7
Nanchang 6
Berlin 5
Norwalk 5
Pune 5
San Mateo 5
Cagliari 4
Guangzhou 4
Jinan 4
Redwood City 4
San Francisco 4
Seattle 4
Tianjin 4
Woodbridge 4
Des Moines 3
Jiaxing 3
Stockholm 3
Tokyo 3
Edinburgh 2
Frankfurt am Main 2
Hefei 2
Kunming 2
L’Aquila 2
Ningbo 2
Redmond 2
Shenyang 2
Sofia 2
Vittuone 2
Wuhan 2
Zhengzhou 2
Zurich 2
Amsterdam 1
Ancona 1
Aquila 1
Atlanta 1
Belgrade 1
Canberra 1
Changchun 1
Chisinau 1
Città Sant'Angelo 1
Dushanbe 1
Espoo 1
Haikou 1
Hamburg 1
Hanoi 1
Houston 1
Huizhou 1
Istanbul 1
Jakarta 1
Kitzingen 1
Lanciano 1
Lisbon 1
Luxembourg 1
Manchester 1
Manila 1
Monaco 1
Nelson 1
New Orleans 1
Nicosia 1
Nizhniy Novgorod 1
Phoenix 1
Quzhou 1
Seoul 1
Shanghai 1
Skopje 1
Surabaya 1
Taizhou 1
Tel Aviv 1
Torre Del Greco 1
Vancouver 1
Vienna 1
Washington 1
Wellington 1
Totale 2.235
Salva come PNG Salva come JPEG
Nome #
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 106
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 91
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 83
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 75
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 71
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 69
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 64
Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases 64
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 63
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 61
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 58
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 58
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 57
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 56
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 54
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 54
Evaluation of prognostic factors for survival in transverse colon cancer 54
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 53
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 51
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 51
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 50
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 50
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 50
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 50
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 49
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 49
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 49
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 48
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 48
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 48
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 48
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 48
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 47
Cancer care after natural disaster: Different countries, similar problems 47
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 45
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 45
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 45
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 44
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 43
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 42
Family history of cancer and DNA damage response genes: Two sides of the same coin? 41
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 41
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 40
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 39
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 39
Studio sul ruolo della storia familiare di neoplasie come fattore predittivo surrogato per l'immunoterapia con inibitori dei checkpoint immunitari PD-1/PD-L1 36
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 36
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 34
Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review 34
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 32
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 32
Rare bone toxicity associated with vismodegib 32
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 32
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report 30
"palliative" or "supportive": Is It Just a Matter of Word? 28
First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen 27
Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice 26
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life 26
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 25
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 24
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 14
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 13
Totale 2.919
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020258 0 0 0 0 0 14 91 16 64 10 1 62
2020/2021423 13 58 2 58 55 8 58 9 75 6 60 21
2021/2022209 4 1 16 8 11 4 3 19 23 2 23 95
2022/20231.193 65 95 9 148 88 114 2 89 516 6 43 18
2023/2024389 38 7 17 20 29 110 3 49 0 17 19 80
2024/2025349 46 28 119 101 55 0 0 0 0 0 0 0
Totale 2.919